Durvalumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer

  • STATUS
    Recruiting
  • End date
    Sep 3, 2023
  • participants needed
    18
  • sponsor
    Georgetown University
Updated on 3 July 2022
platelet count
systemic therapy
serum bilirubin level
pemetrexed
neutrophil count
follicle stimulating hormone
durvalumab
cancer chemotherapy
platinum-based chemotherapy
platinum doublet
lung carcinoma

Summary

This is a phase II trial of durvalumab in combination of platinum-based chemotherapy. Patients with stage IV Non-Small-Cell-Lung Cancer (NSCLC) with human immunodeficiency virus (HIV) infection (cohort 1) or hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (cohort 2) will be eligible. Patients will receive standard platinum-based chemotherapy plus durvalumab for 4 cycles (every 3 weeks), followed by durvalumab (with or without pemetrexed for non-squamous NSCLC) maintenance therapy. We hypothesized that Durvalumab in combination with standard chemotherapy is safe and effective for the treatment of stage IV NSCLC in patients with HIV, HBV, or HCV infection.

Description

This is an open-label, non-randomized phase II trial of durvalumab in combination with platinum-based doublet chemotherapy. Patients with stage IV NSCLC with HIV (cohort 1) or HBV/HCV (cohort 2) infection will be eligible. Patients will receive standard chemotherapy plus durvalumab (1500 mg Q3W) every three weeks for 4 cycles, followed by maintenance treatment with durvalumab (1500 mg Q4W; with or without pemetrexed for non-squamous NSCLC per the discretion of the investigator).

Patient will be enrolled into the trial using an optimal two-stage phase II trial design. If 0 of the 7 achieved a response, no further patients will be enrolled in that cohort. If 1 or more of the first 7 patients has a response, accrual would continue until a total of 18 patients have been enrolled in that cohort. Objective response will be evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Safety and tolerability will be evaluated by assessing the incidence of treatment-related grade 3 or higher AEs. Treatment-related grade 3 or higher AEs will be defined as any grade 3 or higher AEs that occur during the first 42 days of treatment and are related to the study treatment. AEs will be evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Subjects will receive 4 cycles of combination treatment: durvalumab (1500 mg every 3 weeks) in combination with platinum-based doublet chemotherapy. The platinum-based doublet chemotherapies (carboplatin plus paclitaxel/nab-paclitaxel vs. pemetrexed plus carboplatin/cisplatin) are dependent on the tumor histology of the subject (squamous vs. non-squamous). Only subjects who achieve stable disease or better radiological response after 4 cycles of induction treatment will be eligible to continue study treatment in maintenance. The choice to treat non-squamous subjects with pemetrexed maintenance after the 4 induction cycles will be determined by the investigator.

Details
Condition Carcinoma, Non-Small Cell Lung
Treatment durvalumab
Clinical Study IdentifierNCT04499053
SponsorGeorgetown University
Last Modified on3 July 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients with stage IV NSCLC who had undergone no previous systemic therapy for stage IV disease
Cohort 1: Patients with HIV must be on an effective combination anti-retroviral therapy (cART) regimen for ≥ 4 weeks Cohort 2: Patients with chronic HBV infection will be eligible. Patients with positive hepatitis B core antibody (anti-HBc) but negative surface antigen (HBsAg) will be eligible. Those with detectable HBV DNA who are negative for HBsAg will also be eligible. For hepatitis C, patients with detectable HCV RNA will be eligible. Those who have completed antiviral therapy for HCV and undetectable HCV RNA will also be eligible
Age > 18 years at time of study entry
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Body weight >30kg
Adequate normal organ and marrow function as defined below
Hemoglobin ≥ 9.0 g/dL
Absolute neutrophil count (ANC) ≥ 1,000 per mm3
Platelet count ≥ 100,000 per mm3
CD4 T-cell count ≥ 100 per mm3 for HIV-infected patients
Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician
AST (SGOT)/ALT (SGPT) ≤2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be ≤5x ULN
Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance
Males: Creatinine CL (mL/min) = [Weight (kg) x (140 - Age)] / [72 x serum creatinine
(mg/dL)] Females: Creatinine CL (mL/min) = [Weight (kg) x (140 - Age) x 0.85] / [72 x
serum creatinine (mg/dL)]
Evidence of post-menopausal status or negative urinary or serum pregnancy test for
female pre-menopausal patients. Women will be considered post-menopausal if they have
been amenorrheic for 12 months without an alternative medical cause. The following
age-specific requirements apply
Women <50 years of age would be considered post-menopausal if they have been
amenorrheic for 12 months or more following cessation of exogenous hormonal
treatments and if they have luteinizing hormone and follicle-stimulating hormone
levels in the post-menopausal range for the institution or underwent surgical
sterilization (bilateral oophorectomy or hysterectomy)
Women ≥50 years of age would be considered post-menopausal if they have been
amenorrheic for 12 months or more following cessation of all exogenous hormonal
treatments, had radiation-induced menopause with last menses >1 year ago, had
chemotherapy-induced menopause with last menses >1 year ago, or underwent
surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or
hysterectomy)
Patient is willing and able to comply with the protocol for the duration of the study
including undergoing treatment and scheduled visits and examinations including follow
up
Must have a life expectancy of at least 12 weeks

Exclusion Criteria

No measurable disease
History of allogenic organ transplantation
Sensitizing EGFR mutations (deletion in exon 19, L858R in exon 21, G719X, and L861Q)
and/or ALK translocations by locally approved laboratory testing including blood-based
liquid biopsy
Coinfection of HIV + HBV or HIV + HCV (coinfection of HIV and HCV allowed if HCV is
cured). Coinfection of HBV and HCV is allowed if otherwise eligible
Receipt of the last dose of anticancer therapy (chemotherapy, targeted therapy) ≤ 21
days prior to the first dose of study treatment
Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy
(chemotherapy, targeted therapy, radiation therapy) with the exception of alopecia
vitiligo, and the laboratory values defined in the inclusion criteria
Patients who have had whole brain radiation therapy (WBRT) during the previous 2 weeks
before treatment (no washout period is required for patients who have received
stereotactic body radiation therapy)
Subject has had major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic)
within 4 weeks prior to starting study drug or has not recovered from side effects of
such procedure (≥ grade 2 AE related to such procedure). Video-assisted thoracic
surgery (VATS) and mediastinoscopy will not be counted as major surgery and subject
can be enrolled in the study ≥ 1 week after the procedure
Active or prior documented autoimmune or inflammatory disorders (including
inflammatory bowel disease [e.g., colitis or Crohn's disease], systemic lupus
erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with
polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The
following are exceptions to this criterion
i. Patients with vitiligo or alopecia ii. Patients with hypothyroidism (e.g
following Hashimoto syndrome) stable on hormone replacement iii. Any chronic skin
condition that does not require systemic therapy iv. Patients without active disease
in the last 5 years may be included
Uncontrolled intercurrent illness, including but not limited to, ongoing or active
infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
angina pectoris, cardiac arrhythmia, interstitial lung disease, or psychiatric
illness/social situations that would limit compliance with study requirement
substantially increase risk of incurring AEs or compromise the ability of the patient
to give written informed consent
Patients with prior or concurrent malignancy whose natural history or treatment does
not have the potential to interfere with the safety or efficacy assessment of the
investigational regimen are eligible for this trial
Previously untreated central nervous system (CNS) metastases or leptomeningeal
disease. Patients who have had whole brain radiation therapy (WBRT) during the
previous 2 weeks before treatment (no washout period is required for patients who have
received stereotactic body radiation therapy)
Active tuberculosis (clinical evaluation that includes clinical history, physical
examination and radiographic findings, and TB testing in line with local practice)
Current or prior use of immunosuppressive medication within 7 days before the first
dose of durvalumab. The following are exceptions to this criterion
i. Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra
articular injection) ii. Systemic corticosteroids at doses not to exceed 20 mg/day of
prednisone or its equivalent iii. Steroids as premedication for hypersensitivity
reactions (e.g., CT scan premedication) iv. Decreasing dose of systemic
corticosteroids after radiation therapy for brain metastasis
Receipt of live attenuated vaccine within 30 days prior to the first dose of
investigational product (IP). Note: Patients, if enrolled, should not receive live
vaccine whilst receiving study treatment and up to 30 days after the last dose of IP
Female patients who are pregnant or breastfeeding or male or female patients of
reproductive potential who are not willing to employ effective birth control
Known allergy or hypersensitivity to any of the study drugs or any of the study drug
excipients
Patients who have received prior anti-PD-1, anti PD-L1 or anti CTLA-4 within 12 months
of the first dose of durvalumab
Judgment by the investigator that the patient is unsuitable to participate in the
study and the patient is unlikely to comply with study procedures, restrictions and
requirements
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note